Ivermectin has become the wonder cure for Covid-19, with numerous trials suggesting that there could be some benefit to utilising the drug. However, the latest trial may debunk all that.
In the largest Ivermectin trial published earlier this month, the study compared the drug to a placebo and discovered “no statistically significant benefit from ivermectin but possible harm from the drug,” reports News24.
According to News24, the trial was conducted in Argentina, with the subsequent results published in BMC Infectious Diseases on July 2. The premise of the study was to determine whether the toted wonder drug could reduce hospitalisations of people who were infected with Covid-19.
The trial included 501 volunteers, of which 250 were randomly assigned ivermectin, and the remaining 251 were assigned to take a placebo, reports Groundup.
According to the study, fourteen people on ivermectin were hospitalised compared to 21 who took the placebo. Another significant difference stood out – four ivermectin patients needed to be placed on ventilators versus three who took the placebo. Although the ivermectin patients needed to be ventilated five days after they joined the study versus ten days for the placebo arm, states Groundup.
While the trial does not have a clear conclusion, it does imply that ivermectin is not the wonder drug it has been promoted to be.
However, the trial may be too small to provide a final answer about the drug’s safety and efficiency. For more information on this study, make sure to visit the BMC Infectious Diseases website.